Global Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Regional Outlook and Forecast, 2021 - 2027

The Global Idiopathic Pulmonary Fibrosis Market size is expected to reach $4.7 billion by 2027, rising at a market growth of 6.9% CAGR during the forecast period.

Idiopathic pulmonary fibrosis (IPF) refers to a type of chronic lung disease wherein the lungs' tissues thicken and stiffen with time. The brain and other organs do not receive adequate oxygen due to the thickening of lung tissues. This disorder causes scar tissue (fibrosis) to form in the lungs, preventing the lungs from adequately transporting oxygen into the bloodstream. People between the ages of 50 and 70 are most commonly affected by the condition. Idiopathic pulmonary fibrosis is a type of interstitial lung disease (commonly known as ILD), a group of lung disorders characterized by inflammation or scarring in the lungs.

Some of the growth catalysts for the market are increased demand for ideal drugs for treating idiopathic pulmonary fibrosis, and favorable reimbursement policies provided by manufacturers and insurance providers in some countries. In addition, the prevalence of the fibrotic disease is on the rise, growing elderly population, and technological breakthroughs in cancer screening and detection are the key trends of the industry. On the other hand, the lack of appropriate disease treatment alternatives, on the other hand, limits market expansion.

In addition, some of the growth factors for the Idiopathic Pulmonary Fibrosis market are the surge in demand for cost-effective pharmaceuticals and the development of improved treatment options and
an increase in the number of people who smoke cigarettes enhances market growth. However, the lack of therapeutic alternatives that can entirely cure the disease would hamper the growth of the idiopathic pulmonary fibrosis market.

IPF affects about 100,000 people in the United States, according to the National Institutes of Health, and 30,000 to 40,000 new cases are discovered each year. IPF is expected to have a global incidence of 10.7 cases per 100,000 person-years in males and 7.4 cases per 100,000 person-years in females. Idiopathic pulmonary fibrosis is expected to affect 20 instances per 100,000 people in men and 13 cases per 100,000 people in women.

COVID-19 Impact Analysis

Coronavirus (COVID-19) was discovered in Wuhan, Hubei Province, China, in December 2019. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is spread between people.

The virus quickly spread across the globe after its discovery in Wuhan. Moreover, this virus causes a variety of symptoms in individuals, ranging from minor to severe. Fever, dry cough, and exhaustion are some of the most prevalent symptoms. Breathing difficulties or shortness of breath, chest pain or pressure, and lack of speech or movement are all dangerous signs. Further, the virus has a significant fatality potential in the elderly population. COVID-19 has been classified as a pandemic by the World Health Organization (WHO) as of March 11, 2020. In addition, only a few vaccinations have been approved for COVID-19 prophylaxis on an emergency basis. As a result, the most crucial approach to inhibit the development of this disease is social distance. Furthermore, numerous countries around the world have implemented state-wide lockdowns in order to maintain social distance.

Market Growth Factors:

The growing rate of Lung Cancer

The increased global prevalence of cancer, rising healthcare costs, and increasing diagnoses have resulted in a vast patient pool undergoing screening procedures. Lung cancer, for example, is the second most prevalent cancer in both women and men, and is expected to impact over 235,000 persons in the United States by 2020, according to the American Society of Clinical Oncology (2020). According to Globocan (Global Cancer Observatory), 64,804 new cases of cancer would be reported in Germany year 2020. According to the research, lung cancer claimed the lives of over 50,000 people in the country, making it the leading cause of death from cancer.

Supportive medications and clinical trials

IPF is a deadly disease that worsens over time and primarily affects the elderly with several comorbidities. Pirfenidone from Genetech and nintedanib from Boehringer Ingelheim Pharma are licensed pharmaceuticals for the treatment of IPF. These treatments help patients live longer by slowing the rate of lung function decline. Pirfenidone has been utilized in over 42,000 people around the world and has anti-fibrotic and anti-inflammatory characteristics. Both drugs are effective in slowing the progression of the condition.

A variety of medicines for IPF are now undergoing clinical testing. For example, MediciNova's Tipelukast is a tiny bioavailable molecule with anti-fibrotic and anti-inflammatory properties, that is designed to suppress gene expression and promote IPF. Interventional tests on the medication are currently in phase 2. Similarly, FibroGen's Pamrevlumab is an antibody-based treatment for IPF that is currently in phase 3 clinical trials.

Marketing Restraining Factor:

High cost of treatment and lack of awareness & qualified professionals

IPF is acknowledged to be one of the rare diseases, with a high healthcare expense that is disproportionate to the disease's prevalence. Because of the high cost of drugs and treatments for idiopathic pulmonary fibrosis, a majority of people are hesitant to use or continue taking them. As a result, the high cost of such treatments makes them unaffordable for people belonging to the low-income category.

In addition, many countries lack awareness and treatment options for IPF. Further, many countries still lack appropriate healthcare infrastructure that devoid their citizens of basic and advanced healthcare services. Considering these aspects, in spite of a large number of people suffering from IPF, a very low number of people get appropriate treatments. Further, many people work in an environment that forces them to breathe in the existence of dust like asbestos fibers, coal dust, silica dust, and metal dust. As a result, such people are more vulnerable to developing lung-related diseases. Hence, these factors are anticipated to slow down the growth of the overall Idiopathic Pulmonary Fibrosis Market during the forecasting period.

Drug Type Outlook

Based on Drug Type, the market is segmented into Pirfenidone and Nintedanib. In 2020, the Pirfenidone segment acquired the largest revenue share of the Idiopathic Pulmonary Fibrosis Market. This is due to the increased use of pirfenidone drugs such as Esbriet and Pirespa around the world. In experimental models of pulmonary fibrosis, this medication possesses a combination of anti-inflammatory, antioxidant, and antifibrotic properties, making it a promising drug with treatment potential for IPF.

Distribution Channel Outlook

Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Providers. The Hospital Pharmacies segment acquired a significant revenue share of the Idiopathic Pulmonary Fibrosis Market in 2020. The main objective of a hospital pharmacy is to keep track of how pharmaceuticals are used in hospitals and other medical facilities. Moreover, these pharmacies help improve patient outcomes with the help of pharmaceutical selection, prescription, procurement, delivery, administration, and review.

Idiopathic Pulmonary Fibrosis Market Report Coverage

Report Attribute	Details
Market size value in 2020	USD 3 Billion
Market size forecast in 2027	USD 4.7 Billion
Base Year	2020
Historical Period	2017 to 2019
Forecast Period	2021 to 2027
Revenue Growth Rate	CAGR of 6.9% from 2021 to 2027
Number of Pages	159
Number of Tables	253
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling
Segments covered	Drug Type, Distribution Channel, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	The growing rate of Lung Cancer Supportive medications and clinical trials
Restraints	High cost of treatment and lack of awareness & qualified professionals

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2020, North America emerged as the leading region in the overall Idiopathic Pulmonary Fibrosis Market. This is due to the strong infrastructure for developmental research, the availability of substantial research funds, and the rise in government initiatives for idiopathic pulmonary fibrosis. Moreover, the region is witnessing a growing number of individuals with IPF, thereby boosting the growth of the regional market.

Free Valuable Insights: Global Idiopathic Pulmonary Fibrosis Market size to reach USD 4.7 Billion by 2027

KBV Cardinal Matrix - Idiopathic Pulmonary Fibrosis Market Competition Analysis

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. is the major forerunner in the Idiopathic Pulmonary Fibrosis Market. Companies such as AstraZeneca PLC, Boehringer Ingelheim International GmbH and Galapagos NV are some of the key innovators in Idiopathic Pulmonary Fibrosis Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.

Recent Strategy Deployed in Idiopathic Pulmonary Fibrosis Market

» Partnerships, Collaborations and Agreements:

• Dec-2021: AstraZeneca teamed up with BenevolentAI, the British artificial intelligence company. Following this collaboration, AstraZeneca included a novel target for idiopathic pulmonary fibrosis (IPF) in its offerings, which was discovered with the help of the artificial intelligence-driven medication discovery platform of BenevolentAI. Under this collaboration, the two companies would leverage AI to allow researchers to manage the difficult disease landscape, and uncover novel targets with the potential for the treatment of underlying causes and prevent disease growth.
• Nov-2020: Galapagos signed a license agreement with OncoArendi Therapeutics, a Polish innovative biotechnology company that focuses on research, development, and commercialization of innovative small molecule drugs to treat respiratory diseases and cancer. Following the agreement, the two companies aimed to develop and commercialize OncoArendi’s OATD-01. Moreover, Idiopathic pulmonary fibrosis (IPF) and other disorders with a fibrotic component can be treated with OATD-01, a Phase 2-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor.
• Aug-2020: AstraZeneca signed a licensing agreement with Redx Pharma, a drug discovery and development company. Under this agreement, AstraZeneca would advance the molecular into clinical trials to treat fibrotic disorders such as idiopathic pulmonary fibrosis (IPF), a chronic, progressive, irreversible, and usually deadly interstitial lung disease1 with few treatment options.
• Jun-2020: Galapagos joined hands with e-therapeutics, a drug discovery, and development company. Following the collaboration, the two companies would develop new treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. Moreover, the collaboration aimed to discover new approaches to modulate one particular mechanism involved in IPF and other fibrotic conditions.  

» Acquisitions and Mergers:

• Feb-2020: Roche took over Promedior, a Lexington, MA-based clinical-stage biotechnology company. Following the acquisition, Roche would gain access to Promedior's lead product candidate, PRM-15, a recombinant form of human pentraxin-2 that can treat different types of systemic fibrotic diseases.

» Approvals and Trials:

• Mar-2020: Boehringer Ingelheim received U.S. Food and Drug Administration (FDA) approval for Ofev (nintedanib) as the first treatment for individuals suffering from chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. In the Phase III INBUILD trial, Ofev delayed lung function decreased by 57 percent compared to placebo throughout the whole study group, as measured by the annual rate of reduction in forced vital capacity.
• Mar-2020: Roche got the approval by U.S. Food and Drug Administration (FDA) for Therapy Designation (BTD) to Esbriet (pirfenidone) for individuals with unclassifiable interstitial lung disease (uILD). The approval was granted on the basis of data from a phase II trial, which examined the efficacy and safety of Esbriet in uILD.

Scope of the Study

Market Segments Covered in the Report:

By Drug Type

• Pirfenidone
• Nintedanib

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Providers

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• GNI Group Ltd.
• Shionogi & Co., Ltd.
• Mission Therapeutics Ltd.
• Galapagos NV
• FibroGen, Inc.
• AstraZeneca PLC
• F. Hoffmann-La Roche Ltd.
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Biogen, Inc.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Idiopathic Pulmonary Fibrosis Market, by Drug Type
1.4.2 Global Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
1.4.3 Global Idiopathic Pulmonary Fibrosis Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players

Chapter 4. Global Idiopathic Pulmonary Fibrosis Market by Drug Type
4.1 Global Pirfenidone Market by Region
4.2 Global Nintedanib Market by Region

Chapter 5. Global Idiopathic Pulmonary Fibrosis Market by Distribution Channel
5.1 Global Retail Pharmacies Market by Region
5.2 Global Hospital Pharmacies Market by Region
5.3 Global Online Providers Market by Region

Chapter 6. Global Idiopathic Pulmonary Fibrosis Market by Region
6.1 North America Idiopathic Pulmonary Fibrosis Market
6.1.1 North America Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.1.1 North America Pirfenidone Market by Country
6.1.1.2 North America Nintedanib Market by Country
6.1.2 North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.1.2.1 North America Retail Pharmacies Market by Country
6.1.2.2 North America Hospital Pharmacies Market by Country
6.1.2.3 North America Online Providers Market by Country
6.1.3 North America Idiopathic Pulmonary Fibrosis Market by Country
6.1.3.1 US Idiopathic Pulmonary Fibrosis Market
6.1.3.1.1 US Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.3.1.2 US Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.1.3.2 Canada Idiopathic Pulmonary Fibrosis Market
6.1.3.2.1 Canada Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.3.2.2 Canada Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.1.3.3 Mexico Idiopathic Pulmonary Fibrosis Market
6.1.3.3.1 Mexico Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.3.3.2 Mexico Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.1.3.4 Rest of North America Idiopathic Pulmonary Fibrosis Market
6.1.3.4.1 Rest of North America Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.3.4.2 Rest of North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2 Europe Idiopathic Pulmonary Fibrosis Market
6.2.1 Europe Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.1.1 Europe Pirfenidone Market by Country
6.2.1.2 Europe Nintedanib Market by Country
6.2.2 Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2.2.1 Europe Retail Pharmacies Market by Country
6.2.2.2 Europe Hospital Pharmacies Market by Country
6.2.2.3 Europe Online Providers Market by Country
6.2.3 Europe Idiopathic Pulmonary Fibrosis Market by Country
6.2.3.1 Germany Idiopathic Pulmonary Fibrosis Market
6.2.3.1.1 Germany Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.3.1.2 Germany Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2.3.2 UK Idiopathic Pulmonary Fibrosis Market
6.2.3.2.1 UK Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.3.2.2 UK Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2.3.3 France Idiopathic Pulmonary Fibrosis Market
6.2.3.3.1 France Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.3.3.2 France Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2.3.4 Russia Idiopathic Pulmonary Fibrosis Market
6.2.3.4.1 Russia Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.3.4.2 Russia Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2.3.5 Spain Idiopathic Pulmonary Fibrosis Market
6.2.3.5.1 Spain Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.3.5.2 Spain Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2.3.6 Italy Idiopathic Pulmonary Fibrosis Market
6.2.3.6.1 Italy Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.3.6.2 Italy Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2.3.7 Rest of Europe Idiopathic Pulmonary Fibrosis Market
6.2.3.7.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.3.7.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3 Asia Pacific Idiopathic Pulmonary Fibrosis Market
6.3.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.1.1 Asia Pacific Pirfenidone Market by Country
6.3.1.2 Asia Pacific Nintedanib Market by Country
6.3.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3.2.1 Asia Pacific Retail Pharmacies Market by Country
6.3.2.2 Asia Pacific Hospital Pharmacies Market by Country
6.3.2.3 Asia Pacific Online Providers Market by Country
6.3.3 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country
6.3.3.1 China Idiopathic Pulmonary Fibrosis Market
6.3.3.1.1 China Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.3.1.2 China Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3.3.2 Japan Idiopathic Pulmonary Fibrosis Market
6.3.3.2.1 Japan Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.3.2.2 Japan Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3.3.3 India Idiopathic Pulmonary Fibrosis Market
6.3.3.3.1 India Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.3.3.2 India Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3.3.4 South Korea Idiopathic Pulmonary Fibrosis Market
6.3.3.4.1 South Korea Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.3.4.2 South Korea Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3.3.5 Singapore Idiopathic Pulmonary Fibrosis Market
6.3.3.5.1 Singapore Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.3.5.2 Singapore Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3.3.6 Malaysia Idiopathic Pulmonary Fibrosis Market
6.3.3.6.1 Malaysia Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.3.6.2 Malaysia Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3.3.7 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market
6.3.3.7.1 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.3.7.2 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4 LAMEA Idiopathic Pulmonary Fibrosis Market
6.4.1 LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.1.1 LAMEA Pirfenidone Market by Country
6.4.1.2 LAMEA Nintedanib Market by Country
6.4.2 LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4.2.1 LAMEA Retail Pharmacies Market by Country
6.4.2.2 LAMEA Hospital Pharmacies Market by Country
6.4.2.3 LAMEA Online Providers Market by Country
6.4.3 LAMEA Idiopathic Pulmonary Fibrosis Market by Country
6.4.3.1 Brazil Idiopathic Pulmonary Fibrosis Market
6.4.3.1.1 Brazil Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.3.1.2 Brazil Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4.3.2 Argentina Idiopathic Pulmonary Fibrosis Market
6.4.3.2.1 Argentina Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.3.2.2 Argentina Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4.3.3 UAE Idiopathic Pulmonary Fibrosis Market
6.4.3.3.1 UAE Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.3.3.2 UAE Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4.3.4 Saudi Arabia Idiopathic Pulmonary Fibrosis Market
6.4.3.4.1 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.3.4.2 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4.3.5 South Africa Idiopathic Pulmonary Fibrosis Market
6.4.3.5.1 South Africa Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.3.5.2 South Africa Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4.3.6 Nigeria Idiopathic Pulmonary Fibrosis Market
6.4.3.6.1 Nigeria Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.3.6.2 Nigeria Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4.3.7 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market
6.4.3.7.1 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.3.7.2 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel

Chapter 7. Company Profiles
7.1 GNI Group Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Shionogi & Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Mission Therapeutics Ltd.
7.3.1 Company Overview
7.4 Galapagos NV
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 FibroGen, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals and Trials:
7.7.5.2 Acquisitions and Mergers:
7.8 Bristol Myers Squibb Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. Biogen, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

TABLE 1 Global Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 2 Global Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements – Idiopathic Pulmonary Fibrosis Market
TABLE 4 Approvals and Trials – Idiopathic Pulmonary Fibrosis Market
TABLE 5 Acquisition and Mergers – Idiopathic Pulmonary Fibrosis Market
TABLE 6 Global Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 7 Global Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 8 Global Pirfenidone Market by Region, 2017 - 2020, USD Million
TABLE 9 Global Pirfenidone Market by Region, 2021 - 2027, USD Million
TABLE 10 Global Nintedanib Market by Region, 2017 - 2020, USD Million
TABLE 11 Global Nintedanib Market by Region, 2021 - 2027, USD Million
TABLE 12 Global Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 13 Global Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 14 Global Retail Pharmacies Market by Region, 2017 - 2020, USD Million
TABLE 15 Global Retail Pharmacies Market by Region, 2021 - 2027, USD Million
TABLE 16 Global Hospital Pharmacies Market by Region, 2017 - 2020, USD Million
TABLE 17 Global Hospital Pharmacies Market by Region, 2021 - 2027, USD Million
TABLE 18 Global Online Providers Market by Region, 2017 - 2020, USD Million
TABLE 19 Global Online Providers Market by Region, 2021 - 2027, USD Million
TABLE 20 Global Idiopathic Pulmonary Fibrosis Market by Region, 2017 - 2020, USD Million
TABLE 21 Global Idiopathic Pulmonary Fibrosis Market by Region, 2021 - 2027, USD Million
TABLE 22 North America Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 23 North America Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 24 North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 25 North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 26 North America Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 27 North America Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 28 North America Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 29 North America Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 30 North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 31 North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 32 North America Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 33 North America Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 34 North America Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 35 North America Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 36 North America Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 37 North America Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 38 North America Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 39 North America Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 40 US Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 41 US Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 42 US Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 43 US Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 44 US Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 45 US Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 46 Canada Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 47 Canada Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 48 Canada Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 49 Canada Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 50 Canada Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 51 Canada Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 52 Mexico Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 53 Mexico Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 54 Mexico Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 55 Mexico Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 56 Mexico Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 57 Mexico Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 58 Rest of North America Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 59 Rest of North America Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 60 Rest of North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 61 Rest of North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 62 Rest of North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 63 Rest of North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 64 Europe Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 65 Europe Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 66 Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 67 Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 68 Europe Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 69 Europe Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 70 Europe Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 71 Europe Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 72 Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 73 Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 74 Europe Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 75 Europe Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 76 Europe Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 77 Europe Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 78 Europe Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 79 Europe Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 80 Europe Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 81 Europe Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 82 Germany Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 83 Germany Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 84 Germany Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 85 Germany Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 86 Germany Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 87 Germany Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 88 UK Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 89 UK Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 90 UK Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 91 UK Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 92 UK Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 93 UK Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 94 France Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 95 France Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 96 France Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 97 France Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 98 France Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 99 France Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 100 Russia Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 101 Russia Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 102 Russia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 103 Russia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 104 Russia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 105 Russia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 106 Spain Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 107 Spain Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 108 Spain Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 109 Spain Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 110 Spain Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 111 Spain Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 112 Italy Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 113 Italy Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 114 Italy Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 115 Italy Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 116 Italy Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 117 Italy Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 118 Rest of Europe Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 119 Rest of Europe Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 120 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 121 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 122 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 123 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 124 Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 125 Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 126 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 127 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 128 Asia Pacific Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 129 Asia Pacific Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 130 Asia Pacific Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 131 Asia Pacific Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 132 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 133 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 134 Asia Pacific Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 135 Asia Pacific Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 136 Asia Pacific Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 137 Asia Pacific Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 138 Asia Pacific Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 139 Asia Pacific Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 140 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 141 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 142 China Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 143 China Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 144 China Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 145 China Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 146 China Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 147 China Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 148 Japan Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 149 Japan Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 150 Japan Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 151 Japan Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 152 Japan Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 153 Japan Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 154 India Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 155 India Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 156 India Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 157 India Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 158 India Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 159 India Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 160 South Korea Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 161 South Korea Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 162 South Korea Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 163 South Korea Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 164 South Korea Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 165 South Korea Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 166 Singapore Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 167 Singapore Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 168 Singapore Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 169 Singapore Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 170 Singapore Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 171 Singapore Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 172 Malaysia Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 173 Malaysia Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 174 Malaysia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 175 Malaysia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 176 Malaysia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 177 Malaysia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 178 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 179 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 180 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 181 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 182 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 183 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 184 LAMEA Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 185 LAMEA Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 186 LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 187 LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 188 LAMEA Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 189 LAMEA Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 190 LAMEA Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 191 LAMEA Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 192 LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 193 LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 194 LAMEA Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 195 LAMEA Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 196 LAMEA Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 197 LAMEA Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 198 LAMEA Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 199 LAMEA Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 200 LAMEA Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 201 LAMEA Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 202 Brazil Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 203 Brazil Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 204 Brazil Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 205 Brazil Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 206 Brazil Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 207 Brazil Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 208 Argentina Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 209 Argentina Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 210 Argentina Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 211 Argentina Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 212 Argentina Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 213 Argentina Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 214 UAE Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 215 UAE Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 216 UAE Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 217 UAE Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 218 UAE Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 219 UAE Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 220 Saudi Arabia Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 221 Saudi Arabia Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 222 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 223 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 224 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 225 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 226 South Africa Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 227 South Africa Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 228 South Africa Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 229 South Africa Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 230 South Africa Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 231 South Africa Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 232 Nigeria Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 233 Nigeria Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 234 Nigeria Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 235 Nigeria Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 236 Nigeria Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 237 Nigeria Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 238 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 239 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 240 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 241 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 242 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 243 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 244 Key Information – GNI Group Ltd.
TABLE 245 Key Information – Shionogi & Co., Ltd.
TABLE 246 Key Information – Mission Therapeutics Ltd.
TABLE 247 Key Information – Galapagos NV
TABLE 248 Key Information – FibroGen, Inc.
TABLE 249 Key Information – AstraZeneca PLC
TABLE 250 key information – F. Hoffmann-La Roche Ltd.
TABLE 251 Key Information – Bristol Myers Squibb Company
TABLE 252 Key Information – Boehringer Ingelheim International GmbH
TABLE 253 Key Information – Biogen, Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.